| pirfenidone / Generic mfg. |
| Completed | 2 | 180 | NA | Pirfenidone 1200 mg, Prolonged-release pirfenidone, Pirfenidone 1800 mg, Placebo | Jorge L Poo | Liver Fibrosis, Cirrhosis, Liver, Chronic Liver Disease | 12/21 | 03/23 | | |
| Ongoing | 2 | 90 | Europe, RoW | Pirfenidone, Capsule, hard, Esbriet | Clinical Trials Unit, Rigshospitalet, F. Hoffmann La Roche Ltd, F. Hoffmann La Roche Ltd. | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s)., A lung disease in which the small airway branches (bronchioles) are compressed and narrowed by scar tissue (fibrosis) and/or inflammation. This leads to partial or complete blockage of the airways., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-000149-30: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease |
|
|
| Not yet recruiting | 2 | 270 | Europe | Esbriet, Capsule, Esbriet | University Hospitals of Leicester NHS Trust, Genentech Inc | Rheumatoid arthritis associated interstitial lung disease (RA-ILD), ILD is inflammation and scarring of the lung tissue. In the case of RA-ILD, the scarring is caused when the over-active immune system attacks the lungs causing scarring to build up over time., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-001781-41: Evaluation of safety and tolerability of pirfenidone in pulmonary scarring due to asbestos, a multicenter study Evaluatie van de veiligheid en tolerantie van Pirfenidone bij littekens in de long door asbest, een multicenter studie |
|
|
| Not yet recruiting | 2 | 10 | Europe | Pirfenidone, SAP-10163800, Capsule, Esbriet (Pirfenidone) | Nederlandse Vereniging van Artsen voor longziekten en Tuberculose, Roche BV | asbestosis asbestose, pulmonary scars due to asbestos littekens in de long door asbest, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-002701-94: CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS. ENSAYO CLINICO PARA EVALUAR LA EFICACIA DE LA PIRFENIDONA EN LA REDUCCIÓN DE LA INFLAMACIÓN PULMONAR EN PACIENTES CON SILICOSIS Y FIBROSIS MASIVA PROGRESIVA. |
|
|
| Ongoing | 2 | 18 | Europe | Capsule, hard, Tablet, Esbriet | Fundación para la Gestión de la Investigación Biomédica de Cádiz, Instituto de Salud Carlos III | progressive massive fibrosis fibrosis masiva progresiva, silicosis of lung silicosis de pulmón, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 2 | 148 | Europe | Pirfenidone, Placebo | Institut d'Investigació Biomèdica de Bellvitge | Fibrotic Pulmonary Sequelae Post-COVID19 Infection | 01/22 | 06/22 | | |
NCT03221257: Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate |
|
|
| Completed | 2 | 51 | US | Pirfenidone (PFD), Esbriet, Placebo (Plac), Inactive capsule, Mycophenolate Mofetil (MMF), generic for Cellcept | Michael Roth, University of Michigan, Genentech, Inc., University of California, Los Angeles | Scleroderma, Systemic, Interstitial Lung Disease | 03/22 | 06/22 | | |
NCT04461587: Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis |
|
|
| Completed | 2 | 50 | US | Pirfenidone, Esbriet | Pulmonary Research of Abingdon, LLC, Genentech, Inc. | Coal Workers' Pneumoconiosis (Complicated) | 11/22 | 11/22 | | |
NCT05118256: Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis |
|
|
| Recruiting | 2 | 18 | Europe | Pirfenidone Oral Tablet, Esbriet | Instituto de investigación e innovación biomédica de Cádiz | Silicosis, Progressive Massive Fibrosis, Complicated Silicosis | 11/22 | 11/23 | | |
| Not yet recruiting | 2 | 50 | US | Pirfenidone, Esbriet | Jesse Roman, Genentech, Inc. | Hermansky Pudlak Syndrome, Interstitial Lung Disease | 12/22 | 12/22 | | |
NCT06142318: Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | Pirfenidone, Placebo | Nanfang Hospital, Southern Medical University | Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer, Pirfenidone | 01/25 | 06/25 | | |
NCT05542615: Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). |
|
|
| Recruiting | 2 | 60 | RoW | Prolonged-Release Pirfenidone | University of Guadalajara, Hospital Central Militar | Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder | 12/23 | 01/24 | | |
| Active, not recruiting | 2 | 240 | Europe, US, RoW | Placebo, Pirfenidone, Deupirfenidone | PureTech | Idiopathic Pulmonary Fibrosis | 10/24 | 08/25 | | |
NCT05373914: RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Not yet recruiting | 2 | 200 | NA | Cudetaxestat (BLD-0409), Cudetaxestat, Control: Matching Placebo | Blade Therapeutics | Idiopathic Pulmonary Fibrosis | 12/23 | 03/24 | | |
ChiCTR2000034397: Gemcitabine, plus nab-paclitaxel, pirfenidone for pancreatic cancer with liver metastasis: a phase II, single center, single arm study |
|
|
| Not yet recruiting | 2 | 33 | | gemcitabine plus nab-paclitaxel, pirfenidone | Sun Yat-Sen Cancer Center; Sun Yat-Sen Cancer Center, Sponsered by company | Pancreatic cancer | | | | |
ChiCTR2200064594: A Randomized Controlled Multicenter Clinical Trial of Efficacy and Safety of Pirfenidone Capsules in the Treatment of Grade 2 and 3 Radiation-induced Lung Injury |
|
|
| Recruiting | 2 | 126 | | Pirfenidone capsules 100 mg/capsule + basic treatment plan ;Basic treatment plan | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Beijing Contini Pharmaceutical Co. LTD | radiation-induced lung injury | | | | |
NCT05704166: PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients |
|
|
| Recruiting | 2 | 214 | RoW | Pirfenidone/Placebo, Pirfenidone Capsules/Placebo | Fujian Medical University Union Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Acute Lung Injury, Prevention | 12/24 | 12/24 | | |
| Recruiting | 2 | 200 | US | Pirfenidone, ESBRIET, matching placebo | Veterans Medical Research Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), San Diego Veterans Healthcare System, University of California, San Diego, University of California, San Francisco, Genentech, Inc. | Chronic Kidney Disease | 05/24 | 12/24 | | |
| Active, not recruiting | 2 | 100 | RoW | Pirfenidone Oral Capsule, Placebo Oral Capsule | Shanghai Zhongshan Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Myocardial Fibrosis | 05/24 | 06/24 | | |
| Recruiting | 2 | 270 | RoW | HEC585, Pirfenidone, Placebo | Sunshine Lake Pharma Co., Ltd. | Idiopathic Pulmonary Fibrosis | 05/24 | 05/25 | | |
| Recruiting | 2 | 60 | US | Pirfenidone, Placebo | University of Alabama at Birmingham, Congressionally Directed Medical Research Programs | Recurrent Acute Pancreatitis | 02/28 | 02/28 | | |
NCT06241560: A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood |
|
|
| Not yet recruiting | 2 | 20 | NA | BI 1015550, Nerandomilast, Pirfenidone, Esbriet | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | 08/25 | 08/25 | | |
NCT05801133: Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors |
|
|
| Recruiting | 2 | 41 | RoW | Pirfenidone, PFD, AiSiRui | Hubei Cancer Hospital | Lung Cancer | 03/25 | 09/25 | | |
2021-001555-14: Assessment of the effect of Wharton's jelly mesenchymal stem cellpreparation (WJMSCs) in the treatment of fibrotic interstitial lungdiseases Ocena wpływu preparatu mezenchymalnych komórek macierzystychgalarety Whartona (WJMSCs) w leczeniu zwłókniającychśródmiąższowych chorób płuc |
|
|
| Not yet recruiting | 1/2 | 45 | Europe | allogeneic mesenchymal stem cells derived from Wharton’s jelly, Allogeneic WJ-MSC, Suspension for injection, Tablet, Capsule, soft, Esbriet, Ofev 100mg, Ofev 150mg | Medical University of Gdańsk, Medical Reaserch Agency | fibrotic interstitial lung disease zwłókniająca śródmiąższowa choroba płuc, idiopathic pulmonry fibrosis and pulmonary fibrosis after COVID-19 Samoistne włóknienie płuc oraz włóknienie płuc po COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04467723: Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC |
|
|
| Recruiting | 1/2 | 25 | US | Atezolizumab, Pirfenidone | University of Kansas Medical Center, parkview cancer institute | NSCLC Stage IV, NSCLC, Recurrent | 08/24 | 08/25 | | |
NCT03109288: Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) |
|
|
| Recruiting | 1/2 | 250 | US | Pioglitazone, clemastine fumarate, Dantrolene, Pirfenidone | National Institute of Allergy and Infectious Diseases (NIAID) | Multiple Sclerosis | 01/25 | 01/29 | | |
NCT05350371: Safety and Tolerability of Pirfenidone in Acute Pancreatitis |
|
|
| Recruiting | 1/2 | 60 | US | Pirfenidone Oral Tablet, Placebo | University of Alabama at Birmingham, Mayo Clinic | Pancreatitis, Acute | 03/25 | 07/25 | | |
